In order to have the evaluation of efficacy, safety and to detect the side effects of two Peginterferons, the authors have implemented a matched pair study on treatment naive chronic hepatitis C patients treated with Peginterferon alfa-2b or Peginterferon alfa-2a plus Ribavirin. There are 100 naive chronic hepatitis C patients aged from 18 to 68, divided into two equal groups in clinical manifestations. Group I were treated with Peg-IFN alfa-2a, 180mcg qweek plus Ribavirin 15mg/kg/day
Group II were treated with peg-IFN alfa-2b 1.5mcg/kg/week plus Ribavirin 15mg/kg/ day. The treatment last for 48 weeks and being followed up in 24 weeks after completed. The result of sustained viral response of Group I was not different from of Group II on total patients (82 percent vs. 84 percent, p 0.05). The relapse in two groups were also similar (12 percent vs. 8 percent, p 0.05). In conclusion, the sustained viral response rate is similar in naive chronic hepatitis C patients treated with Peg-IFN alfa-2a or Peg-IFN alfa-2b. Side effect of leukocytopenia more frequently occurs in treatment with Peg-IFN alfa-2b. Using erythropoietin was similar in two groups.